Substituted phenylalkanoic acids for the treatment of diabetes
申请人:The Institute for Pharmaceutical Discovery LLC
公开号:US20040248937A1
公开(公告)日:2004-12-09
The present invention relates to compounds and pharmaceutically acceptable salts of formula (I):
1
which are useful in the treatment of metabolic disorders related to insulin resistance or hyperglycemia. These compounds include inhibitors of protein tyrosine phosphatase (PTP-1B) that are useful in the treatment of diabetes and other PTP-1B mediated diseases, such as cancer, neurodegenerative diseases and the like. The compounds of the invention are also useful in pharmaceutical compositions and methods of treating the aforementioned conditions.
The present invention relates to compounds and pharmaceutically acceptable salts of formula (I), which are useful in the treatment of metabolic disorders related to insulin resistance or hyperglycemia. These compounds include inhibitors of protein tyrosine phosphatase (PTP-1B) that are useful in the treatment of diabetes and other PTP-1B mediated diseases, such as cancer, neurodegenerative diseases and the like. The compounds of the invention are also useful in pharmaceutical compositions and methods of treating the aforementioned conditions.
[EN] The present invention relates to compounds and pharmaceutically acceptable salts of formula: (I) which are useful in the treatment of metabolic disorders related to insulin resistance or hyperglycemia. These compounds include inhibitors of protein tyrosine phosphatase (PTP-1B) that are useful in the treatment of diabetes and other PTP-1B mediated diseases, such as cancer, neurodegenerative diseases and the like. The compounds of the invention are also useful in pharmaceutical compositions and methods of treating the aforementioned conditions. [FR] La présente invention concerne des composés et des sels pharmaceutiqument acceptables de la formule (I) utiles dans le traitement de troubles métaboliques liés à la résistance à l'insuline ou à l'hyperglycémie. Ces composés contiennent des inhibiteurs de la tyrosine phosphatase protéique (PTP-1B) qui sont utiles dans le traitement de diabètes et autres maladies liées à la PTP-1B, telles que le cancer, les maladies neuro-dégéneratives et équivalent. Les composés de l'invention sont utiles dans des compositions pharmaceutiques et procédés de traitement des états susmentionnés.